ATE485045T1 - Medikament auf basis eines monoesters von steroiden mit langkettigen fettsäuren - Google Patents

Medikament auf basis eines monoesters von steroiden mit langkettigen fettsäuren

Info

Publication number
ATE485045T1
ATE485045T1 AT06829511T AT06829511T ATE485045T1 AT E485045 T1 ATE485045 T1 AT E485045T1 AT 06829511 T AT06829511 T AT 06829511T AT 06829511 T AT06829511 T AT 06829511T AT E485045 T1 ATE485045 T1 AT E485045T1
Authority
AT
Austria
Prior art keywords
monoesters
steroids
fatty acids
long chain
chain fatty
Prior art date
Application number
AT06829511T
Other languages
English (en)
Inventor
Anna Petroni
Original Assignee
Anna Petroni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anna Petroni filed Critical Anna Petroni
Application granted granted Critical
Publication of ATE485045T1 publication Critical patent/ATE485045T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
AT06829511T 2005-12-13 2006-12-12 Medikament auf basis eines monoesters von steroiden mit langkettigen fettsäuren ATE485045T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002377A ITMI20052377A1 (it) 2005-12-13 2005-12-13 Medicamento a base di monoestere di steroidi con acidi grassi a catena lunga
PCT/EP2006/011925 WO2007068434A2 (en) 2005-12-13 2006-12-12 Medicament based on a monoester of steroids with long chain fatty acids

Publications (1)

Publication Number Publication Date
ATE485045T1 true ATE485045T1 (de) 2010-11-15

Family

ID=37831602

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06829511T ATE485045T1 (de) 2005-12-13 2006-12-12 Medikament auf basis eines monoesters von steroiden mit langkettigen fettsäuren

Country Status (7)

Country Link
US (1) US20100317639A1 (de)
EP (1) EP1962856B1 (de)
AT (1) ATE485045T1 (de)
DE (1) DE602006017736D1 (de)
ES (1) ES2354289T3 (de)
IT (1) ITMI20052377A1 (de)
WO (1) WO2007068434A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3174544B1 (de) * 2014-07-31 2020-12-09 Universita' Degli Studi Di Cagliari Ester eines phospholipids mit konjugierter linolsäure zur behandlung von psychiatrischen störungen mit neuroinflammatorischer und neurodegenerativer basis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2192935A (en) * 1934-04-07 1940-03-12 Schering Corp Esters of polycyclic alcohols and a method of producing the same
GB455264A (en) * 1935-04-08 1936-10-08 Schering Kahlbaum Ag Process for the manufacture of esters of polycyclic alcohols
US4147783A (en) * 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness

Also Published As

Publication number Publication date
EP1962856A2 (de) 2008-09-03
WO2007068434A2 (en) 2007-06-21
ES2354289T3 (es) 2011-03-11
WO2007068434A3 (en) 2007-09-07
EP1962856B1 (de) 2010-10-20
US20100317639A1 (en) 2010-12-16
ITMI20052377A1 (it) 2007-06-14
DE602006017736D1 (de) 2010-12-02

Similar Documents

Publication Publication Date Title
Tiwari The role of serratiopeptidase in the resolution of inflammation
TN2021000028A1 (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
BRPI0507622B8 (pt) composto baseado em ácido hialurônico, processo para preparar um composto ou um sal do mesmo, composição farmacêutica, produto medicinal e dispositivo médico para uso humano ou veterinário, e,uso de composto ou de um sal do mesmo
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
ATE373018T1 (de) Esterderivate von hyaluronsäure zur herstellung von hydrogelmaterialien durch photohärtung
SG10201903512SA (en) Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
NO20076382L (no) Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer
EP2316444A3 (de) Verwendung von Alkandicarbonsäuren und Retinoiden zur Behandlung von Rosacea und anderen entzündlichen Hauterkrankungen
CO6150156A2 (es) Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares
RU2014114649A (ru) Синтез эластического волокна in vivo
CL2012002560A1 (es) Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).
MX2010004042A (es) Refrescantes fisiologicos a base de lactoil esteres de lactato de mentilo.
ES2155517T3 (es) Derivados del acido n-acetil-neuraminico y procedimientos para su preparacion.
ATE485045T1 (de) Medikament auf basis eines monoesters von steroiden mit langkettigen fettsäuren
EA201070918A1 (ru) Применение ранолазина для лечения сердечно-сосудистых заболеваний
BR0111683A (pt) Remédios para doenças alérgicas e processo de produção do mesmo
CN106806244A (zh) 一种瓜拉那瘦身身体乳
WO2019224602A3 (en) Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease
MX2011012595A (es) Composicion farmaceutica que comprende el uso de derivados de prostaglandina para modular las funciones mediadas por claudina y el tratamiento de trastornos dermatologicos.
FR2884423B1 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
MC200058A1 (fr) Analogues du dipeptide citrullinylarginine et leurs utilisations dermatologiques comme agents de soin et de traitement
Silva et al. Polyunsaturated Fatty Acids Potentiate The Effects Of Mesenchymal Stromal Cells In Sepsis-Induced Acute Respiratory Distress Syndrome
PE20060082A1 (es) Derivados de aminoacidos como mediadores del transporte inverso de colesterol
Naldi Melanoma excision: how deep must we go?

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties